Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Viking Therapeutics grew its share prices by 11.89 percent on Wednesday to finish at $34.34 apiece as investors took heart from comments that the weight loss industry appears larger than visible, sparking robust prospects for its own drug candidate which has a “best-in-class” potential. In his presentation at an annual conference, CEO Brian Lian said that market interest in the weight loss industry “is probably broader than visible,” noting that more parties are circling around and appearing very intrigued. Viking Therapeutics Inc. (NASDAQ:VKTX) is underway with late-stage clinical trials for the oral and injectable versions of its own weight loss drug candidate, VK2735—a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. According to Lian, the first group of the Phase 3 study, called Vanquish-1, was over-enrolled ahead of schedule. Meanwhile, it is targeting to complete enrollment of the Vanquish-2 within the f
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Is Viking Therapeutics (VKTX) Now Attractive After A Strong DCF Upside Signal [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Says “I'm a Eli Lilly Guy” When Asked About Viking Therapeutics [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal ObesityPR Newswire
- What Investors Should Know About a Viking Therapeutics Insider's $2 Million Stock Sale [Yahoo! Finance]Yahoo! Finance
- Is Viking Therapeutics (VKTX) Quietly Recasting Its Metabolic Ambitions With VK2735 And New Leadership? [Yahoo! Finance]Yahoo! Finance
VKTX
Earnings
- 10/22/25 - Miss
VKTX
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- VKTX's page on the SEC website